Alamar Biosciences has partnered with leading universities to launch a national-scale project profiling 21,000 plasma samples from 10,000 Alzheimer's and related dementia participants using its NULISAseq Neuro 220 panel. This initiative aims to accelerate biomarker discovery for neurodegenerative diseases by creating a publicly accessible dataset linked to extensive clinical and genetic data. The project supports AI-driven research and will host a national data challenge to foster new analytical methods. This effort could improve diagnosis, treatment, and understanding of Alzheimer's and related conditions.
XRP fell below $1, marking it the weakest major token recently, even as Ripple secured a new partnership with South Korea's Jeonbuk Bank for near real-time cross-border payments. The deal highlights Ripple's expansion in institutional adoption but do...
Bitcoin rose 2.3% to $64,282 after a 3% drop last week, driven by anticipation of a White House meeting on cryptocurrency innovation involving President Trump and industry leaders. Despite this recovery, Bitcoin ETFs saw $390 million in outflows, the...
A Coldcard hardware wallet exploit first identified in March 2021 has resulted in the theft of roughly 714.8 Bitcoin from 192 victims, with most losses occurring between 2021 and 2022. The attack exploited a seed-generation flaw in the Coldcard firmw...
Multiconsult ASA reported a 7.8% increase in net operating revenues to NOK 1,527.1 million in Q2 2026, driven by higher billing rates and increased capacity. EBITA rose to NOK 108.2 million, improving the margin to 7.1%, supported by good sales and s...
Bitmine Immersion Technologies owns 4.8% of the total Ethereum supply, holding over 5.8 million ETH valued at $9.6 billion, and has $11.4 billion in total crypto assets including Bitcoin and strategic investments. The company has repurchased over 20....
